Search results for: cancer

Does Methotrexate Increase Skin Cancer Risk?

November 16, 2015 • By Lara C. Pullen, PhD

A recent study connects the use of immunosuppressant and biologic agents to an increased risk of nonmelanoma skin cancer in patients being treated for RA and IBD…... [Read More]

Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer

November 4, 2015 • By Will Boggs, MD

NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study. “We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of… [Read More]

FOCIS 2015: TET Protein Regulation May Provide Insights for Cancer Treatment

September 15, 2015 • By Catherine Kolonko

A presentation given during FOCIS 2015, the 15th annual meeting of the Federation of Clinical Immunity Societies in June 2015 in San Diego, focused on advances in stem cell research related to treatment of cancer and the function that particular enzymes play in disease. Anjana Rao, PhD, professor at the La Jolla Institute for Allergy… [Read More]

2014 ACR/ARHP Annual Meeting: Autoimmune Connective Tissue Diseases and Cancer

April 1, 2015 • By Susan Bernstein

Links between autoimmunity, malignancy prompt rheumatologists to include cancer screening for patients... [Read More]

When Rheumatology and Cancer Collide

March 1, 2015 • By Simon M. Helfgott, MD

Chronic inflammation, cancer and autoimmunity are inextricably linked... [Read More]

Can Scleroderma Be Cured by Curing Cancer?

March 31, 2014 • By Lara C. Pullen, PhD

Research review... [Read More]

FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira

October 19, 2021 • By U.S. Food & Drug Administration

On Oct. 15, the U.S. Food & Drug Administration (FDA) approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to and interchangeable with (i.e, may be substituted for) its reference product Humira (adalimumab) for Cyltezo’s approved uses. Cyltezo is the second interchangeable biosimilar… [Read More]

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

October 14, 2021 • By Vanessa Caceres

As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib… [Read More]

How Do Reduced-Dose Glucocorticoids Plus Rituximab Affect ANCA-Associated Vasculitis?

October 13, 2021 • By Lara C. Pullen, PhD

Furuta et al. evaluated the benefits of reducing glucocorticoid doses during remission induction for patients with ANCA-associated vasculitis. The researchers found a reduced-dose-glucocorticoid-plus-rituximab regimen was noninferior to a regimen of high-dose glucocorticoids plus rituximab in these patients.... [Read More]

Psoriatic Arthritis Treatment Update

October 13, 2021 • By Mary Choy, PharmD, BCGP, FASHP

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA… [Read More]